Royalty Pharma plc — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Royalty Pharma acquires biopharmaceutical royalty interests and funds product development; results are driven by underlying product sales and changes in estimated royalty cash flows. Figures below are in U.S. dollars unless noted.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Total income and other revenues | $536.3M | $573.5M | $1,758.5M | $1,671.5M |
| Operating income | $151.4M | $192.2M | $879.3M | $789.7M |
| Consolidated net income | $122.1M | $220.4M | $982.5M | $840.1M |
| Net income attributable to Royalty Pharma plc | $72.1M | $142.7M | $640.5M | $498.9M |
| Basic and diluted EPS | $0.16 | $0.32 | $1.43 | $1.14 |
| Net cash from operating activities | $573.5M | $538.8M | $2,215.2M | $1,574.0M |
Operating margin, calculated as operating income divided by total income and other revenues, was approximately 28.2% in Q3 2023 versus 33.5% in Q3 2022, and 50.0% for the first nine months of 2023 versus 47.2% in 2022. These are derived figures, not company-reported non-GAAP margins.
- Royalty cash receipts: Total royalty receipts were $737.4M in Q3, up from $703.9M, and $2,597.4M for nine months, up 26.8% year over year. Nine-month receipts included a $475M Zavzpret approval milestone. Adjusted Cash Receipts, a company-defined non-GAAP measure, were $2,312.8M, up 34.0%; Adjusted Cash Flow was $1,959.7M, up 52.0%.
- Cash and liquidity: Cash and cash equivalents were $936.4M at September 30, down from $1,710.8M at year-end 2022. Operating cash flow was partly offset by $1,072.6M of investing outflows and $1,916.9M of financing outflows. The company cited operating cash generation and its undrawn revolving facility as liquidity sources.
- Debt: Notes had $6.3B principal outstanding and $6.13B carrying value at September 30. The company repaid $1.0B of notes at maturity in September. Its $1.5B revolving facility had no borrowings at quarter-end; it drew $350M in October, leaving $1.15B available. The company reported compliance with debt covenants.
- Capital returns: Nine-month dividends totaled $269.0M, or $0.60 per Class A share. The company repurchased 8.9M shares for approximately $278.6M under its $1.0B authorization.
Material changes versus prior periods
- Q3 total income declined 6.5%, and attributable net income fell 49.4%, mainly reflecting lower financial royalty asset income and less favorable non-operating gains than in 2022. Financial royalty asset income declined 7.8% in Q3, including lower Imbruvica and Tysabri income.
- Nine-month revenue increased 5.2% and attributable net income rose 28.4%. Results benefited from the Zavzpret milestone and related recognized income, recently acquired royalties, and gains on available-for-sale debt securities. This was partly offset by lower Imbruvica and Tysabri performance and the expiration of Januvia and Janumet royalties.
- The provision for changes in expected cash flows from financial royalty assets was $277.1M in Q3 and $637.2M year to date, versus $305.1M and $595.4M, respectively, in 2022. The provision is substantially non-cash and can move with forecasts of product sales and royalty duration.
- Q3 R&D funding expense increased to $50.5M, primarily from a $50M Cytokinetics milestone; nine-month expense declined to $51.5M from $126.6M in 2022. G&A increased to $190.6M for nine months, partly due to management payments tied to royalty cash receipts.
Outlook, risks and unusual items
- No numerical full-year guidance is provided in the supplied filing text. Management expects to continue evaluating and making royalty acquisitions, but notes that transaction timing and annual investment levels are uncertain. It stated that available capital, operating cash flow and revolving credit access should support obligations and planned investments for the foreseeable future.
- In October 2023, the company acquired additional Evrysdi royalties for $1.0B upfront and drew $350M on its revolver to fund part of the acquisition. PTC may sell additional royalty interests under options through 2025–2026, subject to stated terms.
- Portfolio performance is exposed to product demand, pricing and reimbursement pressure, competition, patent or exclusivity changes, regulatory outcomes, and the actions of third-party marketers. Tysabri faces biosimilar competition; management cited pricing, competition and channel pressure, while Imbruvica receipts have been affected by competition and a suppressed market.
- Concentration remains material: the five largest product franchises represented 66% of nine-month royalty receipts, excluding the Zavzpret milestone. Vertex’s cystic fibrosis franchise accounted for 36% of nine-month income from other revenues; Vertex was also the largest royalty payor, representing 31% of the current portion of financial royalty assets.
- Financial royalty asset valuations and GAAP income rely on forecasts and other significant estimates; changes can generate substantial non-cash provisions. Development-stage investments carry approval and commercialization uncertainty. The company also identifies leverage, interest-rate, foreign-exchange, tax, Manager-related and counterparty risks.
- The filing reports ordinary-course legal proceedings but says outcomes and damages generally cannot be estimated; no accrual was recorded, and management did not expect existing proceedings to materially harm the company. Disclosure controls were deemed effective; no material change in internal control was reported.
Important facts for investors to verify
- Whether growth in royalty receipts persists after excluding the one-time $475M Zavzpret milestone, and how product-level trends evolve.
- Underlying sales forecasts, royalty durations and provision assumptions—especially for Imbruvica, Tysabri and other assets with reported cash-flow forecast reductions.
- Funding and returns from the $1.0B Evrysdi acquisition, any further PTC royalty sales, and the resulting debt and liquidity position.
- Portfolio concentration and exposure to product competition, pricing/reimbursement changes, patent expiry and development-stage trial outcomes.
- Debt covenant headroom, interest costs, and the allocation of cash among acquisitions, dividends and share repurchases.